Abstract: Provided is a composition for treating and/or preventing cognitive impairment or dementia. The composition for treating and/or preventing cognitive impairment or dementia containing hydrogen gas, wherein the composition is used to allow the hydrogen gas to be inhaled by a subject. The concentration of the hydrogen gas to be inhaled is, for example, 0.5 to 18.3 vol %. The concentration of the hydrogen gas to be inhaled is, for example, 1 to 10 vol %. For example, the time of inhalation of the hydrogen gas is at least 10 minutes or longer per inhalation, and the frequency of inhalation of the hydrogen gas is once or more per day.

Abstract: An object of the present invention is to provide means for treating post-traumatic stress disorder or a blast-induced traumatic brain injury-protective agent. The present invention provides a pharmaceutical composition containing hydrogen as an active ingredient, used for treating post-traumatic stress disorder or protecting against blast-induced traumatic brain injury.

Abstract: The present application provides a radiation damage protecting agent comprising hydrogen gas as an active ingredient at a concentration of 18.5% by volume or less, for treating or alleviating, in a hyperbaric capsule under a pressure higher than standard atmospheric pressure, radiation damage in a human patient who has been exposed to radiation or who has received or receives radiotherapy, and a hyperbaric capsule for administering a hydrogen gas-containing therapeutic agent such as the radiation damage protecting agent to a patient including a human.

Abstract: A thermoplastic elastomer composition including (A) ethylene rubber by 10 to 90 wt %, and (B) propylene polymer by 10 to 90 wt %, where a total amount of the thermoplastic elastomer composition is 100 wt %, is provided. A pressed sheet obtained by press-molding the thermoplastic elastomer composition under molding conditions has a sink-in temperature of 115° C. or higher. The sink-in temperature is measured based on JIS K7196-1991 as a temperature measured when a pressure load sinks in from a sheet surface by 100 ?m. The molding conditions are such that the thermoplastic elastomer composition is hot press molded at a temperature of 200° C. with a maximum pressure of 10 MPa for 5 min, and thereafter cold press molded at a temperature of 23° C. with a maximum pressure of 10 MPa for 5 min, so as to prepare the pressed sheet.

Abstract: The present invention provides a composition for prevention and/or improvement of encephalitis and/or meningitis. More specifically, the present invention provides a composition for prevention and/or improvement of encephalitis and/or meningitis and a symptom associated with the encephalitis and/or meningitis in a subject, comprising molecular hydrogen as an active ingredient.

Abstract: A thermoplastic elastomer composition including (A) ethylene rubber by 10 to 90 wt %, and (B) propylene polymer by 10 to 90 wt %, where a total amount of the thermoplastic elastomer composition is 100 wt %, is provided. A pressed sheet obtained by press-molding the thermoplastic elastomer composition under molding conditions has a sink-in temperature of 115° C. or higher. The sink-in temperature is measured based on JIS K7196-1991 as a temperature measured when a pressure load sinks in from a sheet surface by 100 ?m. The molding conditions are such that the thermoplastic elastomer composition is hot press molded at a temperature of 200° C. with a maximum pressure of 10 MPa for 5 min, and thereafter cold press molded at a temperature of 23° C. with a maximum pressure of 10 MPa for 5 min, so as to prepare the pressed sheet.

Abstract: The present application provides a composition for improving or preventing human renal diseases, containing molecular hydrogen as an active ingredient, for example, a composition for improving or preventing renal diseases in a human patient having acute or chronic nephritis, renal failure, and/or nephrotic syndrome, for example, for improving urinary protein and urinary protein/urinary creatinine ratio to a normal range, and a method for improving renal diseases by administering the composition to the patient.

Abstract: The present invention provides a composition for prevention and/or improvement of a genetic disorder. More specifically, the present invention provides a composition for prevention and/or improvement of a genetic disorder and a symptom associated with the genetic disorder in a subject, comprising molecular hydrogen as an active ingredient.

Abstract: The present invention provides a composition for regulating intracellular signal transduction. More specifically, the present invention provides a composition for prevention and/or improvement of a symptom associated with intracellular signal transduction in a subject, comprising molecular hydrogen as an active ingredient.

Abstract: The present invention provides a composition for prevention and/or improvement of pneumonia. More specifically, the present invention provides a composition for prevention and/or improvement of pneumonia and a symptom associated with pneumonia in a subject, comprising molecular hydrogen as an active ingredient.

Abstract: The present invention provides a composition for prevention and/or improvement of inflammatory bowel disease. More specifically, the present invention provides a composition for prevention and/or improvement of inflammatory bowel disease and a symptom associated with inflammatory bowel disease in a subject, comprising molecular hydrogen as an active ingredient.

Abstract: The present invention provides a method or a composition for promotion of improvement of postoperative recovery. More specifically, the present invention provides a composition for promotion of recovery from or improvement of surgical invasion and/or a symptom associated with a surgery in a subject undergoing the surgery, comprising molecular hydrogen as an active ingredient, and a method for promotion of recovery from or improvement of surgical invasion and/or a symptom associated with a surgery in a subject undergoing the surgery, comprising administering a composition comprising molecular hydrogen as an active ingredient to the subject.

Abstract: A method for treating schizophrenia, comprising administering a composition containing a therapeutically effective amount of hydrogen gas to a subject in need of the treatment, by inhalation, is provided by the present invention.

Abstract: This application provides a composition comprising hydrogen gas or dissolved hydrogen as an active ingredient for suppressing or preventing abnormality in the intestinal environment of a subject, wherein the abnormality is selected from the group consisting of bacterial translocation and bacterial species composition abnormality of intestinal flora.

Abstract: An object of the present invention is to provide means for treating post-traumatic stress disorder or a blast-induced traumatic brain injury-protective agent. The present invention provides a pharmaceutical composition containing hydrogen as an active ingredient, used for treating post-traumatic stress disorder or protecting against blast-induced traumatic brain injury.

Abstract: A thermoplastic elastomer composition contains components (A), (B), (C), and (D), wherein the weight ratio of component (C) to component (D) is ?0.1 and <2, component (A) is an ethylene random copolymer containing ?50% and ?90% of a monomer unit derived from ethylene by weight relative to the component (A) and a monomer unit derived from at least one monomer selected from the group consisting of ?-olefins having a number of carbon atoms of ?3 and ?10, component (B) is a polymer containing >50% and ?100% of a monomer unit derived from propylene by weight relative to the component (B), component (C) is a copolymer containing an ethylene polymerization block and an ethylene-?-olefin copolymerization block, and component (D) is an ethylene polymer containing >90% and ?100% of a monomer unit derived from ethylene by weight relative to the component (D).

Abstract: This application provides a composition for suppressing or preventing metastasis of a cancer, or for suppressing growth of an end stage cancer with metastasis and/or a metastatic cancer(s) therefrom, in a subject having a cancer, the composition comprising gaseous hydrogen as an active ingredient, as well as a method for suppressing or preventing metastasis or suppressing growth of an end stage cancer with metastasis and/or a metastatic cancer(s) therefrom in a subject, comprising administering this composition to the subject having a cancer.

Abstract: A method for treating schizophrenia, comprising administering a composition containing a therapeutically effective amount of hydrogen gas to a subject in need of the treatment, by inhalation, is provided by the present invention.

Abstract: The present application provides: a composition for improvement of QOL including improvement, suppression or reduction of at least one symptom attributed to cancer selected from the group consisting of cancerous pain, decreased appetite, insomnia, physical fatigue, and poor complexion or coloring in a subject, the composition being characterized by comprising molecular hydrogen as an effective ingredient; and a method for improving QOL in a subject with cancer, comprising administering the composition to the subject.

Abstract: The present application provides: a composition for improving or preventing symptoms of human Parkinson's disease, multiple system atrophy or progressive supranuclear palsy, for example symptoms including at least tremors and/or forward-bending posture, or gait disorder, the composition including a hydrogen gas-containing gas as an effective ingredient; and a method for improving or preventing symptoms of Parkinson's disease, multiple system atrophy or progressive supranuclear palsy, which method comprises administering the composition to a human patient.